Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 618
- 试验地点
- 1
- 主要终点
- Number of patients on first systemic adjuvant therapy with adverse avents (AEs)
研究概览
简要总结
This was a retrospective cohort study using the PharMetrics database. The analysis was conducted using the most recent 5 years of data from the database, January 1, 2015, to October 30, 2020. Included patients were followed for outcome evaluation from the index date (first prescription of treatment, immunotherapy [IO], or targeted therapy [TT] following diagnosis of non-metastatic malignant melanoma and evidence of first lymph node resection), until the first occurrence or end of continuous eligibility or end of the study period.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Immunotherapy (IO)
Patients receiving IO
干预措施: Nivolumab (Drug)
Immunotherapy (IO)
Patients receiving IO
干预措施: Ipilimumab + nivolumab (Drug)
Immunotherapy (IO)
Patients receiving IO
干预措施: Pembrolizumab (Drug)
Targeted therapy (TT)
Patients receiving TT
干预措施: Dabrafenib + trametinib (Drug)
结局指标
主要结局
Number of patients on first systemic adjuvant therapy with adverse avents (AEs)
时间窗: Up to approximately 5 years
次要结局
- Number of patients with AEs following first systemic adjuvant therapy completion/discontinuation.(Up to approximately 5 years)
- Healthcare resource utilization (HCRU) associated with AEs on first systemic adjuvant therapy(Up to approximately 5 years)
- Healthcare costs associated with AEs on first systemic adjuvant therapy(Up to approximately 5 years)
- HCRU associated with AEs following first systemic adjuvant therapy completion/discontinuation(Up to approximately 5 years)
- Healthcare costs associated with AEs following first systemic adjuvant therapy completion/discontinuation(Up to approximately 5 years)